A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study

Journal of Clinical Oncology

Volumn 10, Issue 7, 1992, Pages 1066-1073

  Loehrer Sr , Patrick J ^a   Einhorn, Lawrence H ^b   Elson, Paul J ^b   Crawford, E David ^b   Kuebler, Philip ^b   Tannock, Ian ^b   Raghavan, Derek ^b   Stuart Harris, Robin ^b   Sarosdy, Michael F ^b   Lowe, Bruce A ^b   Blumenstein, Brent ^b   Trump, Donald ^b  

^a INDIANA UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; DRUG FATALITY; FEMALE; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; TUMOR GROWTH; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLADDER NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; COMPARATIVE STUDY; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; LOGISTIC MODELS; MALE; METHOTREXATE; MIDDLE AGE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0026625220     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1992.10.7.1066     Document Type: Article

References (32)

1. Silverberg E: Cancer statistics. Cancer 40:9-26, 1990
2. Yagoda A: Chemotherapy of urothelial tract tumors. Cancer 60:574-585, 1987
3. Natale RB, Yagoda A, Watson RC, et al: Methotrexate: An active drug in bladder cancer. Cancer 47:1246-1250, 1981
4. Blumenreich MS, Yagoda A, Natale RB, et al: Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors. Cancer 50:435-438, 1982
5. Yagoda A, Watson RC, Whitmore WF, et al: Adriamycin in advanced urinary tract cancer: Experience in 42 patients and reviews of the literature. Cancer 39:279-285, 1977
6. Merrin C: Treatment of advanced bladder cancer with cisdiamminedichloro-platinum II: A pilot study. J Urol 119:493-495, 1978
7. Yagoda A, Watson RC, Gonzales-Vitale JC, et al: Cis-dichlorodiammineplatinum II in advanced bladder cancer. Cancer Treat Rep 60:917-923, 1976
8. Rossoff AM, Talley RW, Stephens RL, et al: Phase II evaluation of cis-dichlorodiammineplatinum II in advanced malignancies of the genitourinary and gynecologic organs: A Southwest Oncology Group study. Cancer Treat Rep 63:1557-1564, 1979
9. Peters PC, O'Neill MR: Cisdiamminedichloroplatinum as a therapeutic agent in metastatic transitional cell carcinoma. J Urol 123:375-377, 1980
10. Herr HW: Cisdiamminedichloroplatinum (II) in the treatment of advanced bladder cancer. J Urol 123:853-857, 1980
11. Oliver RTD, Newlands ES, Wiltshaw E, et al: A phase 2 study of cis-platinum in patients with recurrent bladder carcinoma. Br J Urol 53:444-447, 1981
12. Soloway MS, Ikard M, Ford K: Cisdiamminedichloroplatinum (II) in locally advanced and metastatic transitional cell carcinoma. J Urol 123:375-377, 1980
13. DeLena M, Lorusso V, Iacobellis V, et al: Cis-diammine-dichloroplatinum activity in bidimensionally measurable metastatic lesions of bladder carcinoma. Tumori 70:85-88, 1984
14. Sernberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer 64:2448-2458, 1989
15. Mehta CR, Patel NR: A network algorithm for performing Fisher's exact test in R × C contingency tables. J Am Stat Assoc 78:427-434, 1983
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep 50:163-170, 1966
18. Cox DR: Analysis of Binary Data. London, UK, Chapman and Hall, 1970
19. Cox DR: Regression models and life tables (with discussion). J R Stat Soc Series B 34:187-220, 1972
20. Soloway MS, Einstein A, Corder MP, et al: A comparison of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Cooperative Group A Study. Cancer 52:767-772, 1983
21. Troner M, Birch R, Omura GA, et al: Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and c cyclophosphamide in the treatment of bladder (urothelial) cancer: A Southeastern Cancer Study Group Trial. J Urol 137:660-662, 1987
22. Khandekar JD, Elson PJ, DeWys WD, et al: Comparative activity and toxicity of cisdiamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide and DDP in disseminated transitional cell carcinoma of the urinary tract. J Clin Oncol 3:539-545, 1985
23. Hillcoat BL, Raghavan D, Matthews J, et al: A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol 7:706-709, 1989
24. Scher H, Geller N, Curley T, et al: Effect of cumulative dose intensity in survival of patients with urothelial cancer treated with methotrexate, vinblastine, Adriamycin, and cisplatin. Proc Am Soc Clin Oncol 10:165, 1991 (abstr)
25. Tannock I, Gospodarowicz M, Connolly J, et al: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J Urol 142:289-292, 1989
26. Gabrilove JL, Jakobowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Eng J Med 318:1414-1422, 1988
27. Logothetis CJ, Dexeus FH, Finn L, et al: A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050-1055, 1990
28. Toner GC, Panicek DM, Heelan RT, et al: Residual masses after chemotherapy (CT) for non-seminomatous germ cell tumors (NSGCT): Factors predicting need for surgical resection. Proc Am Soc Clin Oncol 8:132, 1989 (abstr)
29. Natale RB, Grossman HB, Crawford ED, et al: Combination cisplatin and dichloromethotrexate in advanced bladder cancer: A Southwest Oncology Group study. Proc Am Soc Clin Oncol 5:104, 1986 (abstr)
30. Carmichael J, Cornbleet MA, MacDougall RH, et al: Cisplatin and methotrexate in the treatment of transitional cell carcinoma of the urinary tract. Br J Urol 57:299-302, 1985
31. Stoter G, Splinter TAW, Child JA: Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol 137:662-667, 1987
32. Harker WG, Meyers FJ, Freiha FS, et al: Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: A Northern California Oncology Group study. J Clin Oncol 3:1463-1470, 1985